Search results for CDKN2A

Anti-CDKN2A/p14ARF antibody [EPR17878], Abcam, AB185620

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CDKN2A/p14ARF antibody [SP271], Abcam, AB216602

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CDKN2A/p16INK4a antibody [1D7D2A1], Abcam, AB201980

This product was changed from ascites to supernatant. Lot no's high than GR286368-6 are from Tissue Culture Supernatant

Anti-CDKN2A/p16INK4a antibody [2D9A12], Abcam, AB54210

Product Specifications Anti-CDKN2A/p16INK4a antibody [2D9A12] (ab54210) is a mouse monoclonal antibody and is validated for use in Flow Cyt, IHC-P in human, rat samples. Anti-CDKN2A/p16INK4a antibody [2D9A12] (ab54210) specifically detects CDKN2A/p16INK4a (UniProt ID: P42771; Molecular weight: 17kDa) and is sold in 100 µL selling sizes. Quality and Validation Abcam's high quality validation processes ensure Anti-CDKN2A/p16INK4a antibody [2D9A12] (ab54210) has high sensitivity and specificity. Anti-CDKN2A/p16INK4a antibody [2D9A12] (ab54210) has been cited over 142 times in peer reviewed journals and is trusted by the scientific community. Anti-CDKN2A/p16INK4a antibody [2D9A12] (ab54210) has 18 independent reviews from customers. Target Information CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a crucial tumor suppressor gene located on chromosome 9p211. It encodes two proteins, p16INK4a and p14ARF, both of which play significant roles in regulating the cell cycle. p16INK4a inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), preventing the progression from the G1 to S phase of the cell cycle. This inhibition is vital for controlling cell proliferation and preventing tumor growth. Mutations or deletions in CDKN2A are frequently associated with various cancers, including melanoma, pancreatic cancer, and head and neck squamous cell carcinoma.

Anti-CDKN2A/p16INK4a antibody [EPR20418], Abcam, AB211542

Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IP, WB in mouse samples. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has been cited over 83 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has 8 independent reviews from customers. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) specifically detects CDKN2A/p16INK4a (UniProt ID: P51480; Molecular weight: 18kDa) and is sold in a convenient trial size to enable initial testing (20 uL) and larger sizes for subsequent scaling up experiments (100 uL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR20418 - ab23242 . CDKN2A, also known as p16INK4a, is a crucial tumor suppressor gene involved in cell cycle regulation and cancer development. It encodes the p16INK4a protein, which inhibits cyclin-dependent kinases (CDKs) 4 and 6, preventing the phosphorylation of the retinoblastoma protein (Rb) and halting cell cycle progression from the G1 to the S phase. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-CDKN2A/p16INK4a antibody [JC2], Abcam, AB267833

Anti-CDKN2A/p16INK4a antibody [PABLO33B], Abcam, AB241543

Product Specifications Anti-CDKN2A/p16INK4a antibody [PABLO33B] (ab241543) is a rat recombinant monoclonal antibody and is validated for use in in mouse samples. Anti-CDKN2A/p16INK4a antibody [PABLO33B] (ab241543) specifically detects CDKN2A/p16INK4a (UniProt ID: P51480; Molecular weight: 18kDa) and is sold in a convenient trial size to enable initial testing (20 µg) and larger sizes for subsequent scaling up experiments (100 µg and 1 mg). Quality and Validation Abcam's high quality manufacturing and validation processes ensure Anti-CDKN2A/p16INK4a antibody [PABLO33B] (ab241543) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-CDKN2A/p16INK4a antibody [PABLO33B] (ab241543) has been confirmed by testing in knockout samples. Related Products Conjugation-ready, carrier free format available for antibody clone PABLO33B - ab252788 . Target Information CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a crucial tumor suppressor gene located on chromosome 9p211. It encodes two proteins, p16INK4a and p14ARF, both of which play significant roles in regulating the cell cycle. p16INK4a inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), preventing the progression from the G1 to S phase of the cell cycle. This inhibition is vital for controlling cell proliferation and preventing tumor growth. Mutations or deletions in CDKN2A are frequently associated with various cancers, including melanoma, pancreatic cancer, and head and neck squamous cell carcinoma. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Want a custom formulation? This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact [email protected]

CDKN2A Interacting Protein (CDKN2AIP) Antibody, Abbexa, abx210511

CDKN2AIP Antibody is a Rabbit Polyclonal against CDKN2AIP.

Anti-CDKN2A/p16INK4a Antibody (R3K92), AntibodySystem, RHE37704

Anti-CDKN2A/p16INK4a Antibody (R3K93), AntibodySystem, RHE37705